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SUMMARY
Background—Tuberculosis (TB) screening in prevention of mother-to-child transmission 
(PMTCT) programs is important to improve TB detection, prevention and treatment.
Methods—As part of a national PMTCT program evaluation, mother-infant pairs attending 6-
week and 9-month immunization visits were enrolled at 141 maternal and child health clinics 
throughout Kenya. Clinics were selected using population-proportion-to-size sampling with 
oversampling in a high HIV prevalence region. The World Health Organization (WHO) TB 
symptom screen was administered to HIV-infected mothers and associations with infant cofactors 
were determined.
Results—Among 498 HIV-infected mothers, 165 (33%) had a positive TB symptom screen. 
Positive maternal TB symptom screen was associated with prior TB (p=0.04). Women with a 
positive TB symptom screen were more likely to have an infant with HIV infection (p=0.02) and 
non-specific TB symptoms, including cough (p=0.003), fever (p=0.05), and difficulty breathing 
(p=0.01). TB exposure was reported by 11% of women, and 15% of TB-exposed women received 
isoniazid preventive therapy.
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Conclusions—Postpartum HIV-infected mothers frequently had a positive TB symptom screen. 
Mothers with a positive TB symptom screen were more likely to have infants with HIV or non-
specific TB symptoms. Integration of maternal TB screening and prevention into PMTCT 
programs may improve maternal and infant outcomes.
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INTRODUCTION
Tuberculosis (TB) is a leading cause of morbidity and mortality among women of 
childbearing age, and maternal TB during pregnancy and postpartum results in poor 
maternal and infant outcomes.1–4 The World Health Organization (WHO) recommends 
routine TB symptom screening (fever, cough, night sweats and weight loss) among HIV-
infected individuals because of their increased risk of TB.5 The TB symptom screen is 
useful to guide clinical evaluation for active TB among those with symptoms and provision 
of isoniazid preventive therapy (IPT) among patients with a negative symptom screen.5 
Integration of TB screening into prevention of mother-to-child-transmission (PMTCT) 
programs has been proposed as an effective way to improve TB detection and prevention 
services for both mothers and infants, but has not been widely implemented.6
TB screening and prevention should optimally occur during both antenatal and postnatal 
services; however, there are no evidence-based models for when and how to integrate 
maternal TB screening. In research cohorts in high HIV and TB prevalence settings, 
approximately 20% of HIV-infected pregnant women had a positive TB symptom screen, 
among whom ~5% had active TB disease.7–9 Fewer studies have assessed postpartum TB 
screening at child immunization visits, which may be another opportunity for TB detection 
and prevention, particularly for HIV-exposed infants.10 Within a national survey of mother-
infant pairs, we assessed the prevalence and correlates of postpartum TB symptoms and TB 
exposure among HIV-infected mothers at 6-week and 9-month infant immunization visits, in 
order to inform future scale-up of TB screening and prevention services within PMTCT 
programs.
METHODS
Study setting
This study was nested within two surveys of the PMTCT program within the maternal child 
health (MCH) services in Kenya conducted between June and December 2013. The National 
PMTCT-MCH Survey used probability proportionate to size sampling to select 120 medium 
(>500 annual antenatal clinic visits) and large volume (>1,000 annual antenatal clinic visits) 
maternal-child health (MCH) clinics within seven of the 8 geographic regions of Kenya. All 
mother-infant pairs attending either 6-week or 9-month infant immunization visits were 
sampled during a single 5-day period. The PMTCT-Nyanza Survey purposively oversampled 
HIV-infected women and their infants in 30 large volume MCH clinics in Nyanza province, 
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a region of high HIV prevalence, during a single 10-day period. Overall, 141 unique 
facilities were visited by a mobile study team for both surveys (Figure 1).
Participants
For this nested analysis, we included data from HIV-infected women and their infants from 
the National PMTCT-MCH Survey and the PMTCT-Nyanza Survey. Women who were not 
willing or able to provide informed consent for the study were excluded.
Procedures
After obtaining informed consent, study staff administered a study questionnaire that 
included questions about sociodemographic information, HIV history (use of combination 
antiretroviral therapy (cART), CD4 count, use of co-trimoxazole prophylaxis), prior clinical 
TB history, TB symptoms, TB exposure in the past 12 months, and use of IPT. TB symptom 
screening included the WHO 4-part symptom screen (fever, cough, weight loss, night 
sweats)5, as well as other TB symptoms including prolonged cough or fever (>2 weeks), 
fatigue, anorexia, and hemoptysis. The WHO TB symptom screen was considered positive if 
a participant reported one or more of the four symptoms. Questions on infant health included 
sex, birth weight, HIV status, use of antiretroviral prophylaxis, BCG vaccination history, 
breastfeeding, nonspecific TB symptoms (cough, fever, difficulty breathing, anorexia), and 
history of hospitalization. Study nurses obtained infant anthropometric measurements 
(weight and height, and collected a blood sample by heel prick (0.5 ml) for HIV DNA PCR 
testing. HIV DNA PCR testing was performed at the Centers for Disease Control (CDC)-
Kenya Medical Research Institute (KEMRI) HIV research laboratory in Kisumu, Kenya.
National Guidelines
Kenyan National TB guidelines recommend that all HIV-infected patients receive TB 
symptom screening as part of intensified TB case finding.11 Patients with a positive TB 
symptom screen are referred for further evaluation, including sputum smear microscopy for 
acid fast bacilli (AFB), sputum GeneXpert MTB/RIF (where available) and chest X-ray. Our 
study did not collect data from study participants on results of these evaluations. WHO and 
Kenyan National TB guidelines recommend provision of IPT for HIV-infected patients >12 
months of age with a negative TB symptom screen, HIV-infected children <12 months of 
age who have had recent contact with active TB disease with no evidence of TB, and for all 
children <5 years irrespective of HIV status who have had recent close contact with a case of 
smear positive TB.11, 12 However, these guidelines were not widely implemented during the 
study period.
Statistical Analysis
Statistical analysis was performed using STATA software, version 13 (StataCorp, College 
Station, Texas). Maternal and infant characteristics at the 6-week and 9-month study visits 
were described using proportions or medians. Maternal cofactors of maternal positive WHO 
TB symptom screen were evaluated using univariate logistic regression, with each cofactor 
as the predictor variable and maternal positive WHO TB symptom screen as the outcome 
variable. Infant cofactors of maternal positive WHO TB symptom screen were evaluated 
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using univariate logistic or linear regression as appropriate, with maternal positive WHO TB 
symptom screen as the predictor variable and each cofactor as the outcome variable. All 
analyses were adjusted to account for clustering within clinics.
Human subjects approval
This study was approved by ethical review boards at the University of Washington, Kenya 
Medical Research Institute, and the Centers for Disease Control and Prevention.
RESULTS
Of 2,819 women attending 6-week or 9-month immunization visits, 498 were HIV-infected 
and included in this analysis; 200 women participated in the National PMTCT-MCH Survey 
and 298 women participated in the PMTCT-Nyanza Survey. Data were available for 260 
HIV-infected mothers at the 6-week immunization visit and 238 mothers from the 9-month 
immunization visit.
Women were a median age of 28 years (Interquartile Range [IQR] 24–32) and had a median 
of 8 years education (IQR 7–11). Most women were taking cART (63%) and median CD4 
count was 483 cells/mm3 (IQR 346–643 cells/mm3). Eleven percent of women had a history 
of TB, a median of 4 years (IQR 2–6) prior to enrollment. Eleven percent (52/484) of 
women reported exposure to a person with active TB in the past year, and 15% (8/52) of TB-
exposed women reported taking IPT (Table 1).
Of infants, 49% were male and median birth weight was 3.2 kg (IQR 2.8–3.5 kg). Nearly all 
infants were BCG-vaccinated (99%), and most (90%) had a BCG scar. Five percent of 
infants were HIV-infected, and 58% of infants were breastfed. Most infants (97%) received 
antiretroviral prophylaxis. Median weight-for-age Z score was −0.32 (IQR −1.19–0.51). 
Seven percent of infants had been hospitalized; none were hospitalized for TB. Nonspecific 
symptoms that could be TB-related were prevalent among infants, including cough (32%), 
fever (22%), difficulty breathing (10%), and anorexia (7%). Infants at 9 months of age had a 
higher prevalence of cough (40% vs 25%, p=0.007), fever (31% vs 15%, p<.001), and 
anorexia (13% vs 2%, p<.001) compared to infants at 6 weeks of age (Table 1).
Thirty-three percent of women had a positive WHO TB symptom screen, reporting either 
current cough, fever, weight loss or night sweats. The most prevalent WHO TB symptom 
was cough (19%), followed by fever (14%), weight loss (11%), and night sweats (9%). 
Positive maternal WHO TB symptom screen was associated with household crowding (≥5 
vs. ≤4 people in home) [OR=1.14 (1.00–1.29), p=0.05] and history of TB disease [OR=1.66 
(1.03–2.68), p=0.04] but not with partner HIV status or reported TB exposure. Women with 
a positive WHO TB symptom screen had a lower median CD4 count (454 vs 498, p=0.06). 
Infants born to a mother with a positive WHO TB screen were more likely to have HIV 
infection (7.6% vs. 2.8%, p=0.02). This association remained significant in multivariate 
analyses adjusted for maternal cART and infant antiretroviral prophylaxis [OR 3.16 (1.36–
7.37), p=0.008]. Mothers with a positive WHO TB screen were more likely to have infants 
with nonspecific TB symptoms, including cough (44% vs 26%, p=.003), fever (30% vs 19%, 
p=0.05), difficulty breathing (16% vs 7%, p=0.01) and anorexia (11% vs 5%, p=0.005) 
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(Table 2). Our findings were consistent in a multivariable model adjusting for geographic 
region and clinic size.
DISCUSSION
In this national survey of 141 MCH clinics, we found that a third (33%) of postpartum HIV-
infected women had a positive WHO TB symptom screen at infant immunization visits. 
Eleven percent of HIV-infected women reported known TB exposure, of whom few received 
IPT.
The prevalence of WHO TB screen positivity among postpartum HIV-infected women in 
this study (33%) was higher than most prior studies in pregnant HIV-infected women 
(~20%) (Figure 2).7–9, 13–16 TB symptoms may be less frequent in pregnancy than 
postpartum due to immunologic and physiologic changes.17, 18 Zenner et al. observed a 
higher incidence of TB disease in the first 6 months postpartum compared to pregnancy and 
hypothesized that this may reflect subclinical TB disease during pregnancy that becomes 
clinically-apparent in the postpartum period.19 Other studies have noted that non-specific or 
absent symptoms in pregnancy can lead to delays in TB diagnosis.20, 21 TB symptom 
screening during the postpartum period may improve diagnostic yield to identify TB disease 
compared to screening during pregnancy, which has only modest sensitivity between 28 and 
50%.7–9, 13 Variable performance of the WHO TB symptom screen has been observed, with 
decreased sensitivity in the context of cART and early TB disease.7, 22, 23 To our knowledge, 
performance of the WHO TB symptom screen during the postpartum period has not been 
previously evaluated. Our data suggest that postpartum TB screening may be useful to 
consider. Further studies to compare performance of TB screening during pregnancy and 
postpartum and to estimate incremental benefit and cost-effectiveness of postpartum TB 
screening will be helpful to determine its role in PMTCT programs.
We found that positive maternal WHO TB screen was associated with history of prior TB, 
household crowing, and immunosuppression, which are known risk factors for active 
TB.24–27 We additionally observed an association between a positive maternal WHO TB 
screen and infant HIV infection. Maternal TB disease has previously been shown to be an 
independent risk factor for infant HIV infection, which may be mediated by immune 
activation and increased HIV replication.28 A positive maternal WHO TB screen in our 
cohort may be a proxy for maternal TB disease or be associated with other mother-to-child 
HIV transmission risk factors that we were not able to adjust for, such as maternal viral load. 
However, the association between maternal TB symptoms and infant HIV infection 
remained significant in multivariable analyses adjusted for use of maternal cART and infant 
antiretroviral prophylaxis. Maternal TB symptoms were also associated with infant 
nonspecific TB symptoms, including cough, difficulty breathing, fever, and anorexia, which 
may represent some cases of undiagnosed infant TB. Older infants were more symptomatic 
at 9 months compared to infants screened at the 6-week immunization visit, which may 
represent a missed opportunity for infant TB prevention through early maternal TB 
diagnosis and IPT administration to TB-exposed infants. Infant TB disease is often not 
recognized clinically and has high fatality, though IPT is effective to prevent TB in young 
children with a known TB contact.29,30 Our study suggests that integration of maternal TB 
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symptom screening into MCH immunization programs could prompt infant TB and HIV 
screening and prevention.
Few women received IPT in this study, which is consistent with limited implementation of 
IPT observed in high TB burden countries.31 IPT is an effective intervention to prevent TB 
disease; in a modeling study, treatment of latent infection had higher impact on decreasing 
global TB incidence compared to improved vaccinations or diagnostics.32 Lack of IPT 
implementation is due to many factors, including clinician decision-making, poor 
dissemination of local guidelines and erratic drug supply chain.33 Improved uptake of IPT is 
a key priority identified in Kenya’s National Tuberculosis, Leprosy, and Lung Health 
strategic plan.34 Clinical providers may be hesitant to use IPT among pregnant and 
postpartum women given lack of adequate safety data and prior reports of maternal deaths 
due to hepatotoxicity in pregnancy and postpartum.35 An ongoing clinical trial (IMPAACT 
1078) that assesses safety and toxicity of IPT during pregnancy and postpartum, will better 
inform future use of IPT in this population.36
Our study had several strengths and limitations. In the context of a national survey, our study 
presented data for a large number of postpartum HIV-infected women in Kenya. Our data 
were not nationally representative since we included the PMTCT-Nyanza Survey to increase 
our sample size of HIV-infected women. Clinical and microbiologic TB diagnostic data were 
not available for mothers or infants; therefore we could not assess performance of the WHO 
TB symptom screen for TB diagnosis in the postpartum period or assess if infants with 
nonspecific TB symptoms had TB disease. Our data on IPT use was limited to women with 
known TB exposure, which may have underestimated overall IPT use.
In conclusion, we found that postpartum HIV-infected mothers in Kenya frequently reported 
TB exposure and positive TB symptom screen, but few received IPT. Maternal positive TB 
symptom screen was associated with infant HIV and nonspecific infant TB symptoms. 
Integration of maternal TB screening and prevention into PMTCT programs may improve 
maternal and infant outcomes.
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Figure 1. 
Maternal and child health clinics surveyed across Kenya. Black circles indicate the National 
PMTCT-MCH Survey and white circles indicate the PMTCT-Nyanza Survey.
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Figure 2. 
Proportion of HIV-infected women with positive WHO TB symptom screen during 
pregnancy (%, 95% CI) in published studies to date.
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